Deficient sensory gating (SG) in schizophrenia is associated with functional outcome and offers a therapeutic target as it is linked to the altered function/expression of the α7 nicotinic acetylcholine receptors (nAChRs). This study analyzed the effects of citicoline (CDP-choline), a supplement with α7 nAChRs agonist properties, on SG in a sample of schizophrenia (SZ) patients. Using a randomized, placebo-controlled, double-blind design the dose-dependent (500 mg, 1000 mg, 2000 mg) and baseline-dependent (deficient versus normal suppressors) effects of CDP-choline on SG were examined using the P50 event-related potential (ERP) index of SG. Overall analysis failed to demonstrate treatment effects but CDP-choline improved SG (500 mg) in the deficient SZ subgroup by increasing suppression of the S2 P50 amplitude. These findings tentatively support α7 nAChR dysfunction in the expression of SG deficits and suggest further trials to assess the effects of sustained α7 nAChR activation on SG with low doses of CDP-choline.
AdlerLECawthraEMDonovanKA. (2005) Improved P50 auditory gating with ondansetron in medicated schizophrenia patients. Am J Psychiatry162: 386–388.
2.
AdlerLEFreedmanRRossRG. (1999) Elementary phenotypes in the neurobiological and genetic study of schizophrenia. Biol Psychiatry46: 8–18.
3.
AdlerLEGerhardtGAFranksR. (1990) Sensory physiology and catecholamines in schizophrenia and mania. Psychiatry Res31: 297–309.
4.
AdlerLEHofferLDWiserA. (1993) Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry150: 1856–1861.
5.
AdlerLEHofferLJGriffithJ. (1992) Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol Psychiatry32: 607–616.
6.
AgutJFontESacristánA. (1983) Bioavailability of methyl-14C CDP-choline by oral route. Arzneimittel-Forschung33: 1045–1047.
7.
AlkondonMAlbuquerqueEX (2006) Subtype-specific inhibition of nicotinic acetylcholine receptors by choline : A regulatory pathway. J Pharmacol Exp Ther318: 268–275.
8.
ArnfredSMChenACGlenthøjBY. (2003) Normal p50 gating in unmedicated schizophrenia outpatients. Am J Psychiatry160: 2236–2238.
9.
BabbSMWaldLLCohenBM. (2002) Chronic citicoline increases phosphodiesters in the brains of healthy older subjects: An in vivo phosphorus magnetic resonance spectroscopy study. Psychopharmacology (Berl)161: 248–254.
10.
BoutrosNNKorzyukoOOliwaG. (2004) Morphological and latency abnormalities of the mid-latency auditory evoked responses in schizophrenia: A preliminary report. Schizophr Res70: 303–313.
11.
BoutrosNZouridakisGRustinT. (1993) The P50 component of the auditory evoked potential and subtypes of schizophrenia. Psychiatry Res47: 243–254.
12.
BramonERabe-HeskethSShamP. (2004) Meta-analysis of the P300 and P50 waveforms in schizophrenia. Schizophr Res70: 315–329.
13.
BrinkmeyerJMobascherAMussoF. (2011) P50 sensory gating and smoking in the general population. Addict Biol16: 485–498.
14.
BrysonGBellM (2003) Initial and final work performance in schizophrenia: Cognitive and symptom predictors. J Nerv Ment Dis191: 87–92.
15.
BuchananRWDavisMGoffD. (2005) A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull31: 5–19.
16.
BuchananRWFreedmanRJavittDC. (2007) Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull33: 1120–1130.
17.
BuchananRWSchwarczR (2011) α7 nicotinic receptor agonists as cognitive treatments: Is less (or less often) more?Biol Psychiatry69: 5–6.
18.
CastnerSASmaginGNPiserTM. (2011) Immediate and sustained improvements in working memory after selective stimulation of α7 nicotinic acetylcholine receptors. Biol Psychiatry69: 12–18.
19.
ChangWPArfkenCLSangalMP. (2011) Probing the relative contribution of the first and second responses to sensory gating indices: A meta-analysis. Psychophysiology48: 980–992.
20.
ClementzBABlumenfeldLDCobbS (1997) The gamma band response may account for poor P50 suppression in schizophrenia. Neuroreport8: 3889–3893.
21.
ConantRSchaussAG (2004) Therapeutic applications of citicoline for stroke and cognitive dysfunction in the elderly: A review of the literature. Altern Med Rev9: 17–31.
22.
CourtJSpurdenDLloydS. (1999) Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: Alpha-bungarotoxin and nicotine binding in the thalamus. J Neurochem73: 1590–1597.
23.
CullumCMHarrisJGWaldoMC. (1993) Neurophysiological and neuropsychological evidence for attentional dysfunction in schizophrenia. Schizophr Res10: 131–141.
24.
DaleckiA (2015) Clarifying the Functional Process Represented by Reduced P50 Suppression in Schizophrenia. PhD Dissertation, pp. 1–161.
25.
De LeonJTracyJMcCannE. (2002) Schizophrenia and tobacco smoking: A replication study in another US psychiatric hospital. Schizophr Res56: 55–65.
26.
de WildeOMBourLJDingemansPM. (2007) Failure to find P50 suppression deficits in young first-episode patients with schizophrenia and clinically unaffected siblings. Schizophr Bull33: 1319–1323.
27.
DiwanACastineMPomerleauCS. (1998) Differential prevalence of cigarette smoking in patients with schizophrenic vs mood disorders. Schizophr Res33: 113–118.
28.
DomjánNCsifcsákGDrótosG. (2012) Different patterns of auditory information processing deficits in chronic schizophrenia and bipolar disorder with psychotic features. Schizophr Res139: 253–259.
29.
FioravantiMBuckleyAEA (2006) Citicoline (Cognizin) in the treatment of cognitive impairment. Clin Interv Aging1: 247–251.
30.
FirstMBSpitzerRLRobertL. (1996) Structured Clinical Interview for DSM-IV Axis I Disorders, Clinical Version (SCID-CV). New York: Biometrics Research, New York State Psychiatric Institute.
31.
FrazierCJRollinsYDBreeseCR. (1998) Acetylcholine activates an alpha-bungarotoxin-sensitive nicotinic current in rat hippocampal interneurons, but not pyramidal cells. J Neurosci18: 1187–1195.
32.
FreedmanR (2014) α7-Nicotinic acetylcholine receptor agonists for cognitive enhancement in schizophrenia. Annu Rev Med65: 245–261.
33.
FreedmanRAdlerLEGerhardtGA. (1987) Neurobiological studies of sensory gating in schizophrenia. Schizophr Bull13: 669–678.
34.
FreedmanRHallMAdlerLE. (1995) Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry38: 22–33.
35.
FuerstDRGallinatJBoutrosNN (2007) Range of sensory gating values and test-retest reliability in normal subjects. Psychophysiology44: 620–626.
36.
García-CobosRFrank-GarcíaAGutiérrez-FernándezM. (2010) Citicoline, use in cognitive decline: Vascular and degenerative. J Neurol Sci299: 188–192.
37.
GrattonGColesMGHDonchinE (1983) A new method for off-line removal of ocular artifact. Electroencephalogr Clin Neurophysiol55: 468–484.
38.
GreenMFKernRSBraffDL. (2000) Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the ‘right stuff’?Schizophr Bull26: 119–136.
39.
GuanZZZhangXBlennowK. (1999) Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain. Neuroreport10: 1779–1782.
40.
HahnBGoldJMBuchananRW (2013) The potential of nicotinic enhancement of cognitive remediation training in schizophrenia. Neuropharmacology64: 185–190.
41.
HarveyPDHowanitzEParrellaM. (1998) Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: A comparison across treatment sites. Am J Psychiatry155: 1080–1086.
42.
HeinrichsRW (2004) Meta-analysis and the science of schizophrenia: Variant evidence or evidence of variants?Neurosci Biobehav Rev28: 379–394.
43.
HongLESummerfeltAMcMahonRP. (2004) Gamma/beta oscillation and sensory gating deficit in schizophrenia. Clin Neurosci Neuropathol15: 88–94.
44.
HongXChanRCZhuangX. (2009) Neuroleptic effects on P50 sensory gating in patients with first-episode never-medicated schizophrenia. Schizophr Res108: 151–157.
45.
HughesJRHatsukamiDKMitchellJE. (1986) Prevalence of smoking among psychiatric outpatients. Am J Psychiatry143: 993–997.
46.
IchikawaJDaiJO'LaughlinIA. (2002) Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without and effect in the nucleus accumbens or Striatum. Neuropsychopharmacology26: 325–339.
47.
JavittDC (2009) Sensory processing in schizophrenia: Neither simple nor intact. Schizophr Bull35: 1059–1064.
48.
JavittDCFreedmanR (2015) Sensory processing dysfunction in the personal experience and neuronal machinery of schizophrenia. Am J Psychiatry172: 17–31.
49.
JavittDCSweetRA (2015) Auditory dysfunction in schizophrenia: Integrating clinical and basic features. Nat Rev Neurosci16: 535–550.
50.
KaySRFiszbeinAOplerLA (1987) The positive and negative syndrome scale for schizophrenia. Schizophr Bull13: 261–276.
51.
KeefeRSFentonWS (2007) How should DSM-V criteria for schizophrenia include cognitive impairment?Schizophr Bull33: 912–920.
52.
KeefeRSHarveyPD (2012) Cognitive impairment in schizophrenia. In: GeyerMGrossG (eds) Novel Antischiphreina Treatments. Handbook of Experimental Pharmacology, vol. 213. Berlin, Heidelberg; Springer, pp. 11–38.
53.
KnottVde la SalleSSmithD. (2013) Baseline dependency of nicotine’s sensory gating actions: Similarities and differences in low, medium and high P50 suppressors. J Psychopharmacol27: 790–800.
54.
KnottVMillarAFisherD (2009a) Sensory gating and source analysis of the auditory P50 in low and high suppressors. NeuroImage44: 992–1000.
55.
KnottVShahDFisherD. (2009b) Nicotine and attention: Event-related potential investigations in nonsmokers. Clin EEG Neurosci40: 11–20.
56.
KnottVSmithDde la SalleS. (2014) CDP-choline: Effects of the procholine supplement on sensory gating and executive function in healthy volunteers stratified for low, medium and high P50 suppression. J Psychopharmacol28: 1095–1108.
57.
KnottVJFisherDJMillarAM (2010) Differential effects of nicotine on P50 amplitude, its gating, and their neural sources in low and high suppressors. Neuroscience170: 816–826.
58.
KnottVJMillarAMMcIntoshJF. (2011) Separate and combined effects of low dose ketamine and nicotine on behavioural and neural correlates of sustained attention. Biol Psychol88: 83–93.
59.
KoikeKHashimotoKTakaiN. (2005) Tropisetron improves deficits in auditory P50 suppression in schizophrenia. Schizophr Res76: 67–72.
60.
KraguljacNVReidMWhiteD. (2012) Neurometabolites in schizophrenia and bipolar disorder: A systematic review and meta-analysis. Psychiatry Res203: 111–125.
61.
KumariVPostmaP (2005) Nicotine use in schizophrenia: The self medication hypotheses. Neurosci Biobehav Rev29: 1021–1034.
62.
LeonardSAdamsCBreeseCR. (1996) Nicotinic receptor function in schizophrenia. Schizophr Bull22: 431–445.
LeonardSGaultJHopkinsJ. (2002) Association of promoter variants in the alpha 7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Arch Gen Psychiatry59: 1085–1096.
65.
LightGAGeyerMAClementzBA. (2000) Normal P50 suppression in schizophrenia patients treated with atypial antipsychotic medications. Am J Psychiatry157: 767–771.
66.
LightGASwerdlowNRRisslingAJ. (2012) Characterization of neurophysiologic and neurocognitive biomarkers for use in genomic and clinical outcome studies of schizophrenia. PLoS One7: e39434.
67.
LiuXHongXChanRC. (2013) Association study of polymorphisms in the alpha 7 nicotinic acetylcholine receptor subunit and catechol-o-methyl transferase genes with sensory gating in first-episode schizophrenia. Psychiatry Res209: 431–438.
68.
Martin-RuizCMHaroutunianVHLongP. (2003) Dementia rating and nicotinic receptor expression in the prefrontal cortex in schizophrenia. Biol Psychiatry54: 1222–1233.
69.
MillerCLFreedmanR (1995) The activity of hippocampal interneurons and pyramidal cells during the response of the hippocampus to repeated auditory stimuli. Neuroscience69: 371–381.
70.
NeumannSABrownSMFerrellRE. (2006) Human choline transporter gene variation is associated with corticolimbic reactivity and autonomic-cholinergic function. Biol Psychiatry60: 1155–1162.
71.
OlincyAHarrisJGJohnsonLL. (2006) Proof-of-concept trial of an α7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry63: 630–638.
72.
OlincyAStevensKE (2007) Treating schizophrenia symptoms with and alpha7 nicotinic agonist, from mice to men. Biochem Pharmacol74: 1192–1201.
73.
PapkeRLBencherifMLippielloP (1996) An evaluation of neuronal nicotinic acetylcholine receptor activation by quaternary nitrogen compounds indicates that choline is selective for the alpha 7 subtype. Neurosci Lett213: 201–204.
74.
PattersonJVHetrickWPBoutrosNN. (2008) P50 sensory gating ratios in schizophrenics and controls: A review and data analysis. Psychiatry Res158: 226–247.
75.
PrickaertsJvan GoethemNPChesworthR. (2012) EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors. Neuropharmacology62: 1099–1110.
76.
RosenheckRDoyleJLeslieD. (2003) Changing environments and alternative perspectives in evaluating the cost-effectiveness of new antipsychotic drugs. Schizophr Bull29: 81–93.
77.
RoweARMercerLCasettiV. (2015) Dementia praecox redux: A systematic review of the nicotinic receptor as a target for cognitive symptoms of schizophrenia. J Psychopharmacol29: 197–211.
StevensKEAdamsCEYonchekJ. (2008b) Permanent improvement in deficient sensory inhibition in DBA/2 mice with increased perinatal choline. Psychopharmacology198: 413–20.
85.
StevensKEMeltzerJRoseGM (1995) Nicotinic cholinergic normalization of amphetamine-induced loss of auditory gating in freely moving rats. Psychopharmacology119: 163–170.
86.
StevensKEWearKD (1997) Normalizing effects of nicotine and a novel nicotinic agonist on hippocampal auditory gating in two animal models. Pharmacol Biochem Behav57: 869–874.
87.
SwartzMSPerkinsDOStroupTS. (2003) Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. Schizophr Bull29: 33–43.
88.
SydserffSSuttonEJSongD. (2009) Selective α7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes. Biochem Pharmacol78: 880–888.
89.
UteshevVVMeyerEMPapkeRL (2002) Regulation of neuronal function by choline and 4OH-GTS-21 through alpha 7 nicotinic receptors. J Neurophysiol89: 1797–1806.
90.
VlcekPBobPRabochJ (2014) Sensory disturbances, inhibitory deficits, and the P50 wave in schizophrenia. Neuropsychiatr Dis Treat10: 1309–1315.
91.
WerkheiserJLSydserffSHubbsSJ. (2011) Ultra-low exposure to α-7 nicotinic acetylcholine receptor partial agonists elicits an improvement in cognition that corresponds with an increase in α-7 receptor expression in rodents: Implications for low dose clinical efficacy. Neuroscience186: 76–87.
92.
WintererGGallinatJBrinkmeyerJ. (2013) Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: A proof-of-mechanism study. Neuropharmacology64: 197–204.
93.
WurtmanRJReganMUlusI. (2000) Effect of oral CDP-choline on plasma choline and uridine levels in humans. Biochem Pharmacol60: 989–992.
